Hepatitis C virus: Here comes all-oral treatment

Cleveland Clinic Journal of Medicine

Volumn 81, Issue 3, 2014, Pages 159-172

  Dugum, Mohannad ^a   O'Shea, Robert ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ((5 (2,4 DIOXO 3,4 DIHYDRO 2H PYRIMIDIN 1 YL) 4 FLUORO 3 HYDROXY 4 METHYLTETRAHYDROFURAN 2 YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; ANTIVIRUS AGENT; DNA DIRECTED RNA POLYMERASE; DRUG DERIVATIVE; FUSED HETEROCYCLIC RINGS; PROTEINASE INHIBITOR; SIMEPREVIR; SULFONAMIDE; URIDINE PHOSPHATE;

ARTICLE; DRUG ANTAGONISM; HEPATITIS C; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DNA-DIRECTED RNA POLYMERASES; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PROTEASE INHIBITORS; SULFONAMIDES; URIDINE MONOPHOSPHATE;

EID: 84897735396     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.81a.13155     Document Type: Article

References (39)

1. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the united states. Clin Infect Dis 2012; 55(suppl 1):S10-S15.
2. Wiesner RH, Sorrell M, Villamil F, International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplant 2003; 9:S1-S9.
3. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.
4. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132:1979-1998.
5. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81:1631-1648.
6. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-288, 288.e1.
7. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39:333-342.
8. Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 2011; 1:590-598.
9. Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 2012; 23:1-12.
10. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
11. Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012; 13:313-323.
12. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(suppl 1):93-104.
13. Manns MP, McCone J, Jr, Davis MN, et al. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int 2013; Aug 2. doi: 10.1111/liv.12300. [Epub ahead of print].
14. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
15. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS- 7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58:663-668.
16. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100-2107.
17. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13:401-408.
18. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34-44.
19. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878- 1887.
20. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877.
21. Zeuzem S, Dusheiko G, Salupere R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial [abstract no.1085]. 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC.
22. Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013; 14:1161-1170.
23. You DM, Pockros PJ. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2013; 14:2581-2589.
24. Jacobson IM, Dore GJ, Foster G, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from Quest-1, a phase III trial [abstract no. 1425]. Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, Netherlands.
25. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial [abstract no. 1413]. Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, The Netherlands.
26. Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from promise, a phase III trial [abstract no. 869b]. Digestive Disease Week; May 18-21, 2013; Orlando, FL.
27. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology epub Oct 31, 2013.
28. Jacobson IM, Ghalib RM, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS- 7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study [abstract LB-3]. 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC.
29. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61(RR-4):1-32.
30. Sulkowski MS, Kang M, Matining R, et al. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCVinfected adults: a randomized, double-blind, phase 1b study. J Infect Dis 2013 Oct 9. [Epub ahead of print].
31. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59:375-382.
32. Yu M, Corsa AC, Xu S, et al. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res 2013; 100:439-445.
33. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58:428-438.
34. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368:1907-1917.
35. Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs 2013; 18:461-475.
36. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixeddose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2013 Nov 1. doi: 10.1016/S0140-6736(13)62121-2. [Epub ahead of print].
37. Drenth JP. HCV treatment-no more room for interferonologists? N Engl J Med 2013; 368:1931-1932.
38. Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 2013; 29:243-249.
39. Afdhal NH, Zeuzem S, Schooley RT, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepatol 2013; 20:745-760.